THERMO FISHER SCIENTIFIC INC. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Thermo Fisher reported Q3 2026 revenue of $12.14B (9% YoY growth; 6% organic), with GAAP diluted EPS of $4.64 (9% growth) and adjusted EPS of $6.68 (15% growth). The company completed its microbiology business divestiture, launched high-impact products (Orbitrap Isora mass spectrometer, EliA CTD 13 autoimmune test, Ion 560 sequencing chip), and expanded operations (AI-Automation Innovation Center in South Korea, automated distribution center in Kentucky). Nine-month results: $35.14B revenue (9% growth; 4% organic), $13.75 diluted EPS (9% growth), $18.15 adjusted EPS (11% growth).
Why this rating
Solid operational execution with mid-single-digit organic growth and margin expansion, but routine quarterly earnings within historical performance range. Immaterial to $154B market cap.
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.